New Genetic Risk Factors Identified for Peanut Allergy
|
By LabMedica International staff writers Posted on 25 Oct 2017 |

Image: Whole genome genotyping arrays are an important tool for discovering variants that contribute to human disease (Photo courtesy of Megan Smolenyak, MBA).
Peanut allergy develops in early life and is rarely outgrown. Roughly 1% of Canadian adults and between 2% and 3% of Canadian children are affected, and the symptoms can be severe and even life threatening.
A new gene associated with peanut allergy has been revealed, offering further evidence that genes play a role in the development of food allergies and opening the door to future studies, improved diagnostics and new treatment options.
An international team of scientists collaborating with those at the University of British Columbia (Vancouver, BC, Canada) scanned more than 7.5 million genetic locations in the DNA of 850 people with peanut allergy and nearly 1,000 people without it, through a genome-wide association study (GWAS), to search for markers that might be linked to food allergy. They recruited the peanut allergy participants from the Canadian Peanut Allergy Registry. The team also conducted a fresh analysis of results pooled from six other genetic studies of populations in North America, Australia, Germany, and the Netherlands. Genotyping of 1,974 individuals (987 cases, 987 controls) was conducted on the Illumina Omni 2.5M+Exome 8v1.1 chip.
The scientists reported that their study is the first to associate the EMSY, BRCA2 Interacting Transcriptional Repressor (EMSY) locus with food allergy, and these findings suggest that the gene plays an important role in the development of not just food allergy but also general allergic predisposition. The gene, called c11orf30/EMSY (EMSY), is already known to play a role in other allergy-related conditions, such as eczema, asthma, and allergic rhinitis. The team also found evidence that five other genetic locations might be involved.
Denise Daley, PhD, an associate professor and senior author of the study, said, “Food allergy is the result of both genetic and environmental factors, but there are surprisingly few data regarding the genetic basis of this condition. The discovery of this genetic link gives us a fuller picture of the causes of food allergies, and this could eventually help doctors identify children at risk.” The study was published on November 10, 2017, in the Journal of Allergy and Clinical Immunology.
Related Links:
University of British Columbia
A new gene associated with peanut allergy has been revealed, offering further evidence that genes play a role in the development of food allergies and opening the door to future studies, improved diagnostics and new treatment options.
An international team of scientists collaborating with those at the University of British Columbia (Vancouver, BC, Canada) scanned more than 7.5 million genetic locations in the DNA of 850 people with peanut allergy and nearly 1,000 people without it, through a genome-wide association study (GWAS), to search for markers that might be linked to food allergy. They recruited the peanut allergy participants from the Canadian Peanut Allergy Registry. The team also conducted a fresh analysis of results pooled from six other genetic studies of populations in North America, Australia, Germany, and the Netherlands. Genotyping of 1,974 individuals (987 cases, 987 controls) was conducted on the Illumina Omni 2.5M+Exome 8v1.1 chip.
The scientists reported that their study is the first to associate the EMSY, BRCA2 Interacting Transcriptional Repressor (EMSY) locus with food allergy, and these findings suggest that the gene plays an important role in the development of not just food allergy but also general allergic predisposition. The gene, called c11orf30/EMSY (EMSY), is already known to play a role in other allergy-related conditions, such as eczema, asthma, and allergic rhinitis. The team also found evidence that five other genetic locations might be involved.
Denise Daley, PhD, an associate professor and senior author of the study, said, “Food allergy is the result of both genetic and environmental factors, but there are surprisingly few data regarding the genetic basis of this condition. The discovery of this genetic link gives us a fuller picture of the causes of food allergies, and this could eventually help doctors identify children at risk.” The study was published on November 10, 2017, in the Journal of Allergy and Clinical Immunology.
Related Links:
University of British Columbia
Latest Molecular Diagnostics News
- Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
- New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
- Ancestry-Informed Genomics Advances Precision Cancer Prognosis
- Long-Read DNA Test Improves Diagnosis of Rare Genetic Diseases
- Genomic Assay Predicts Recurrence Risk in Noninvasive Breast Cancer
- At-Home Urine Collection Kit Enables High-Throughput STI Screening
- Noninvasive Sequencing Test Approaches Invasive Genome Sequencing for Prenatal Screening
- Blood-Based Assay Detects HER2 Mutations to Guide NSCLC Treatment
- New Library Normalization and Amplification Tools Support Oncology Sequencing
- Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
- Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
- AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
- Targeted RNA Test Enhances Genetic Diagnosis in Exome Sequencing
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read more
Ancestry-Informed Genomics Advances Precision Cancer Prognosis
Predicting survival in common cancers remains imprecise despite widespread use of tumor sequencing to guide care. Outcome disparities among patient populations also persist, and the genomic drivers behind... Read more
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more




.jpg)



